Ticker

Partnership leverages BioHorizons' commercial network to broaden availability of Xtant's allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™ BELGRADE, Mont., Aug. 27, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care…

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast today, August 11 th, at 8:30am ET BELGRADE, Mont., Aug. 11, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other…

BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the second quarter ended June 30, 2026, before the start of trading on Tuesday, August 11, 2026.

BELGRADE, Mont., Aug. 4, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 46th Annual Growth Conference, which is being held August 11-13, 2026, in Boston.